AstraZeneca said the US regulator has refused to approve the asthma drug Fasenra for the treatment of chronic rhinosinusitis with nasal polyps, a condition characterized by benign growths that cause pain and congestion.

4gi.tv
AstraZeneca said the US regulator has refused to approve the asthma drug Fasenra for the treatment of chronic rhinosinusitis with nasal polyps, a condition characterized by benign growths that cause pain and congestion.